Triple-negative breast cancer remains one of oncology's most difficult treatment puzzles — aggressive, heterogeneous, and responsive to immunotherapy in only a fraction of patients. What the field has lacked is a reliable early signal to distinguish likely responders from non-responders before surgery. New longitudinal transcriptomic data from a Phase III randomized trial now offer a meaningful step toward that goal.
The NeoTRIPaPDL1 trial enrolled 280 patients with high-risk TNBC, randomizing them to carboplatin plus nab-paclitaxel with or without the PD-L1 inhibitor atezolizumab. Tumor biopsies were collected at baseline and at the start of the second treatment cycle. RNA sequencing across both time points revealed that the absence of detectable tumor cells in early on-treatment biopsies was a strong predictor of surgical pathologic complete response (pCR) in both treatment arms. At baseline, tumors in the chemoimmunotherapy arm that ultimately achieved pCR showed higher proliferation signatures alongside lower stromal and metabolic gene program activity. As treatment progressed, proliferation signatures declined and immune and stromal signatures rose — changes that were amplified in pCR-achieving tumors, especially in those receiving atezolizumab. Immune deconvolution confirmed dynamic tumor microenvironment remodeling, with enrichment of immune cell populations associated with response.
This work is significant for several reasons. Biomarker-guided TNBC treatment has long been hampered by the static, single-timepoint nature of most predictive models. The integration of longitudinal RNA sequencing with XGBoost modeling represents a methodological advance that captures treatment-induced biology rather than merely pre-existing tumor characteristics. The Phase III setting and 280-patient cohort lend credibility that smaller exploratory studies cannot. That said, the findings are correlative, and ferroptosis-related signatures — mentioned in the methodology — are not yet mechanistically interpreted in the available excerpt. Translation to clinical decision tools will require prospective validation. Nonetheless, the early on-treatment biopsy signal is potentially actionable and could inform adaptive treatment strategies in TNBC management.